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Abstract
Background: Patients with rheumatoid arthritis (RA) have shared care between rheumatologists and general
practitioners (GPs). Rheumatologists guide immunosuppressive therapy, whilst GPs rely on analgesia and
glucocorticoid (GC) therapy to manage active disease. The objective of this study was to describe patterns of
GC prescribing for patients with RA in primary care and to determine the influence of patient characteristics
and prescriber.
Methods: Incident RA patients were identified within the Clinical Practice Research Datalink, a United Kingdom
(UK) primary care research database. Descriptive statistics identified patterns of oral GC prescribing. Prescribers
were categorised by their tendency to prescribe GCs (high/low). Logistic regression was used to identify
baseline characteristics associated with GC prescriptions during follow-up and to examine whether baseline
characteristics influenced prescribing differently in high versus low prescribers.
Results: A total of 7777 patients (47 %) received ≥1 GC prescription during follow-up. The average daily dose
was 7.5 mg (IQR 5–15.3 mg). Of those who received GCs, >50 % were prescribed >10 mg/day and 20 % >30 mg/day.
The median proportion of time spent on GCs was 26.3 % (IQR 3.8–70.0 %). Age and cardiovascular disease (CVD) were
associated with increased likelihood of receiving GCs. High prescribers more commonly prescribed GC therapy in older
patients and patients with hypertension.
Conclusions: Half of patients with incident RA received GCs in primary care. Average GC use was 7.5 mg for 25 % of the
time, perhaps higher usage than rheumatologists and GPs might expect. GCs were prescribed more commonly in certain
high-risk populations, including older patients and those with CVD.
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Background
Glucocorticoid (GC) therapy was first introduced as a
treatment for rheumatoid arthritis (RA) over 60 years
ago [1]. GCs have potent anti-inflammatory properties
that rapidly relieve joint pain, swelling and stiffness and
also prevent structural damage [2]. However, they are as-
sociated with significant and predictable side effects
(SEs) of concern to both patients and physicians [3, 4].
In the general population, GCs account for 2.5 % of all
adverse drug reactions leading to hospital admission [5].
Guidelines for rheumatologists advocate short-term use
of GCs [6], an acknowledgment that longer duration of
therapy is associated with increased risk of developing
certain SEs such as infection [7].
The management of RA, a condition where disease ex-
acerbations are part of the natural history, involves
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shared care between the treating rheumatologist and the
patient’s general practitioner (GP). Shared care for pa-
tients with RA is recommended in many international
guidelines and standards of care [8–11] and is common
practice in the UK. In early RA, GPs will often com-
mence initial therapy, which may include simple anal-
gesia, non-steroidal anti-inflammatory drugs (NSAIDs)
and GCs. The treating rheumatologist then guides on-
going management with advice about disease-modifying
anti-rheumatic drugs (DMARDs) and GC use. When
faced with active disease, rheumatologists can initiate
changes to DMARD therapy, however GPs rarely alter
DMARDs and their options for treating disease flares
that occur between rheumatology appointments are usu-
ally limited to GCs and analgesia. In some instances,
GPs will initiate or continue GCs based on the recom-
mendation of the treating rheumatologist, and on other
occasions they may initiate therapy based on their own
clinical judgement. The extent and pattern of GC pre-
scribing for RA in primary care has not been well quan-
tified or described. Therefore, it is not known if doses
and duration of treatment are in keeping with current
guidelines. It is important to understand if certain pa-
tient groups are more likely to receive GCs in primary
care, in particular those at increased risk of developing
GC SEs such as older patients or those with pre-existing
comorbidities. Doctors are known to have differing be-
liefs about GC use and its risks [12–14], therefore it is
also important to understand if certain doctors prescribe
more GCs.
The purpose of this study is to examine how oral GCs
are prescribed for patients with RA in UK primary care.
The primary objective is to describe overall drug utilisa-
tion and patterns of dose and duration. Secondary objec-
tives are to explore the association between patient
characteristics and GC use, and to examine variability in
prescribing practices between prescribers.
Method
Data source
This study utilised the Clinical Practice Research Data-
link (CPRD) [15], an automated database that contains
pseudonymised, prospectively collected electronic med-
ical records from registered UK general practices. In the
UK, healthcare is centralised through GPs and electronic
medical records are maintained and updated within gen-
eral practices. The electronic medical records contain all
primary care details plus information about referrals.
Anonymised prescriber and practice codes are also avail-
able as part of the CPRD dataset.
Studies have found the data held by the CPRD to be
representative of the UK population in terms of age and
gender structure [16, 17]. Validation studies have dem-
onstrated good completeness and accuracy of the data,
particularly for chronic diseases [18, 19]. The CPRD has
its own internal quality measures at the patient and
practice level, including acceptability flags based on con-
tiguity and quality of patient data, and an ‘up to stand-
ard’ date for practices based on continuity of data
recording [20]. UK primary care electronic medical re-
cords use a unique coding system with Read codes
assigned to medical diagnoses and Product codes
assigned to medications [21].
Population and follow-up period
Figure 1 outlines how the cohort of incident RA was
derived. All patients with an RA code recorded in
CPRD between 1 January 1992 and 31 December
2009 were identified. A validated algorithm, shown to
have a sensitivity of 84 % and a specificity of 86 %
when compared to the American College of Rheuma-
tology 1987 revised RA classification criteria [22], was
then used to identify patients with true RA. The RA
diagnosis date was defined as the date of the first RA
code in patients with validated RA. Patients with inci-
dent RA were identified as those with an RA diagno-
sis date on or after the 1 January 1992 and at least
12 months of data recorded prior to diagnosis. Those
with a GC prescription greater than a pre-defined
maximum prednisolone equivalent dose of 100 mg
per day and those aged less than 16 years were
excluded. Follow-up began on the date of RA diagno-
sis and ended when the patient left the practice, died,
the study period finished (31 December 2009) or on
the date data was last collected from the practice,
whichever occurred first.
Outcome measure: glucocorticoid prescriptions
All prescriptions of oral GCs (prednisolone, cortisone,
hydrocortisone, triamcinolone, methylprednisolone,
dexamethasone, bethamethasone, budesonide and defla-
zacort) were identified. Dosages were converted to a
prednisolone-equivalent daily dose. Patients were classi-
fied as having ever or never been prescribed oral GCs
according to receipt of at least one prescription during
their follow-up period.
Predictors: patient characteristics and prescriber tendency
Baseline patient characteristics postulated to poten-
tially influence prescribing were divided into demo-
graphics, other inflammatory indications for GCs,
GC-associated comorbidities (e.g. osteoporosis, dia-
betes) and DMARD use as a surrogate for disease
severity (Table 1). Characteristics and DMARDs were
defined as being present at baseline if the diagnosis
date or first prescription date occurred on or before
RA diagnosis date.
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The primary (i.e. most frequent) prescriber of all medi-
cations was determined for each patient. For each pri-
mary prescriber, the mean proportion of time their
patients spent on GCs during follow-up was calculated
by dividing the length of time spent on GCs by the
length of follow-up time for each patient and then deter-
mining the mean of this value amongst all patients seen
by a given primary prescriber. Prescriber tendency was
then assigned as ‘high’ or ‘low’ prescribers based on
whether the mean proportion of time their patients
spent on GCs was above or below the median value.
Statistical analysis
Descriptive analysis
Descriptive statistics were used to identify patterns of
GC prescribing including: ever use (yes/no), dose,
Table 1 Patient characteristics thought to be potentially relevant to GC prescribing practices
Patient demographics Age
Gender
GC-associated comorbidities Musculoskeletal Osteoporosis, avascular necrosis, myopathy
Endocrine/metabolic Diabetes
Cardiovascular Hypertension, hyperlipidaemia, cardiovascular diseases (myocardial infarction, angina, stroke)
Gastrointestinal Peptic ulcer disease, pancreatitis
Psychological/behavioural Depression, psychosis, insomnia
Inflammatory comorbidities Respiratory Chronic obstructive pulmonary disease, asthma, lower respiratory tract infections
Skin diseases Atopic eczema, cutaneous vasculitis, cutaneous lupus





Other DMARDs Cyclosporine, azathioprine, penicillamine, chloroquine, gold
GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs
Fig. 1 Steps taken to obtain the final cohort
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duration and then dose and duration combined. Ever
use was determined as a binary yes/no variable for the
observation period and separately for the 12 months
prior to diagnosis. For patients who received at least one
GC prescription during the observation period, the
average, lowest and highest prednisolone equivalent
daily doses were determined for the time they were
exposed. The median of these values across all treated
patients was then calculated as a population summary
statistic. The proportion of patients to ever receive
greater than 5 mg, 10 mg, 20 mg and 30 mg per day
was also determined.
The total number of patient years contributing to the
follow-up period was determined, as was the number of
patient years spent on and off GCs. For each patient that
ever received GCs, the duration of follow-up, duration
on GCs and proportion of their total follow-up time
spent on GCs was determined. The median of these
values was calculated as a population summary statistic.
A GC course was defined as consecutive GC prescrip-
tions where the end date of the first prescription was
not more than one calendar day different from the start
date of the next prescription. The median number of
courses per year and the number of patients with a sin-
gle course longer than 3 months and 1 year was deter-
mined. Finally, dose and duration were combined and
the proportion of patients taking more than 5 mg/day
and 10 mg/day for greater than 3 months and 1 year
was calculated.
The number of patients receiving a GC injection and
the median number of injections per patient was also
determined.
Patient characteristics
Univariate logistic regression, adjusted for age and gen-
der, was initially carried out and then stepwise logistic
regression was used to identify baseline patient charac-
teristics associated with GC prescriptions (ever versus
never) including demographics, other possible inflamma-
tory indications, GC-associated comorbidities and
DMARDs.
Prescriber tendency
Univariate logistic regression with an interaction term
was used to determine the effect of prescriber tendency
on the likelihood of receiving a GC prescription (ever
versus never) during follow-up and to test the inter-
action between prescriber tendency and baseline
patient characteristics, including patient demographics
and GC-associated comorbidities.
All analyses were carried out using Stata version 12.1
(StataCorp LP, College Station, TX, USA). The study was
approved by the CPRD Independent Scientific Advisory
Committee (protocol 11_113RA2).
Results
From 1 January 1992 to 31 December 2009, 60,186
patients had at least one code for RA. Once the vali-
dated algorithm was applied to this cohort, 38,884 RA
patients from 636 general practices across the UK were
identified. Of these, 4856 were excluded because their
RA diagnosis date occurred after their end of follow-up
date, 12 were excluded due to a prednisolone-equivalent
daily dose greater than a pre-defined maximum of 100
mg per day and 139 were excluded because they were
aged less than 16 years. A total of 16,536 remained in
the final cohort after the definition for incident RA was
applied as shown in Fig. 1. The majority of the patients
were female (69.3 %) and the median age was 59.8 years
[interquartile range (IQR) 49.0–70.3].
Patterns of GC use
Ever use (yes/no)
There were 7777 (47 %) patients who received at least
one oral GC prescription during the study period and
these patients were classified as ever receiving a GC pre-
scription. There were 3412 patients (20.6 %) who re-
ceived a GC prescription in the 12 months preceding
their diagnosis. Of these, 2940 (86.2 %) were prescribed
further GCs during the follow-up period.
Dose
For those that ever received GCs, the population distri-
bution was a median of 7.5 mg per day (IQR 5–15.3 mg)
for the average dose, 5 mg per day (IQR 2.5–7.5 mg) for
the lowest dose and 15 mg per day (IQR 7.5–30 mg) for
the highest dose. Of those prescribed GCs during
follow-up, 83 % ever received a prednisolone equivalent
daily dose of more than 5 mg/day, 58 % more than
10 mg/day, 39 % more than 20 mg/day and 18 %
more than 30 mg/day.
Duration of GC therapy
Total follow-up time was 92,641 patient years (mean 5.6
years/patient), with 14,382 (15.5 %) patient years spent
on GCs and 78,259 (84.5 %) patient years spent off GCs.
Of the 7777 patients who received GCs during follow-
up, the median duration of follow-up time spent on GCs
was 0.80 years (IQR 0.15–2.56) and the proportion of
time spent on GCs was 26.3 % (IQR 3.8–70.0 %).
Of those who received GCs in the 12 months prior to
diagnosis, the median proportion of time spent on GCs
during that year was 22.7 % (IQR 5.4–67.2 %). Table 2
summarises GC doses and duration of use.
Of those that received GCs, the median number of GC
courses throughout follow-up was 5 (IQR 2–12) and the
median number of courses per year was 1.4 (IQR 0.4–3.0).
The number of patients that received more than two GC
courses per year was 3060 (39.3 % of those that received
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GCs). The median duration of each GC course was 50
days (IQR 21–111). Of those that received GCs, 57.1 % re-
ceived a course longer than 3 months and 13.1 % were
prescribed a GC course lasting longer than 1 year.
Dose and duration of treatment
Of those prescribed GCs, 26.6 % received continuous treat-
ment with more than 5 mg/day for longer than 3 months
and 2.4 % received continuous treatment with greater than
5 mg/day for longer than 1 year. 4.7 % received more than
10 mg/d for more than 3 consecutive months.
GC injections
There were 8373 prescriptions for GC injections (intra-
muscular, intra-articular and periarticular) during the
study period in 2911 patients (37 % total cohort). The
majority were for methylprednisolone (72 %), followed
by triamcinalone (21 %), prednisolone (4 %) and hydro-
cortisone (3 %). The median number of injections per
patient was 2 (IQR 1–3).
Patient factors associated with GC prescribing
Each 10-year increase in age was associated with a 17 %
greater likelihood of being prescribed GCs [odds ratio
(OR), 1.17 95 % confidence interval (CI) 1.14–1.20].
Higher GC prescribing was seen in patients with in-
flammatory comorbidities of the lung: asthma (OR
1.58, 95 % CI 1.42–1.76), chronic obstructive pulmonary
disease (OR 1.63, 95 % CI 1.33–1.99) and lower respiratory
tract infections (OR 1.22, 95 % CI 1.11–1.34). However,
there was no association with inflammatory conditions of
the skin or gastrointestinal tract (GI) tract (Table 3).
The association with pre-existing comorbidities known to
be associated with GC therapy was less consistent. GC pre-
scribing was higher in patients with pre-existing cardiovas-
cular disease (CVD) (OR 1.25, 95 % CI 1.03–1.51) and in
current smokers (OR 1.22, 95 % CI 1.13–1.32) but lower in
patients with diabetes mellitus (DM) (OR 0.71, 95 %
CI 0.62–0.82) and high cholesterol (OR 0.86, 95 % CI
0.76–0.97). There was an association with osteopor-
osis, depression and insomnia seen in the univariate
model, but these factors were not included in the
final multivariate model. There was no significant as-
sociation with other GC-associated comorbidities at
baseline including avascular necrosis, myopathy,
hypertension (HTN), peptic ulcer disease (PUD) or
pancreatitis.
A previous GC prescription prior to RA diagnosis was
the strongest predictor of ever receiving a prescription
post-diagnosis (OR 9.50, 95 % CI 8.51–10.60). GC pre-
scribing was lower with baseline methotrexate and sulfa-
salazine use, but higher with leflunomide and ‘other’
DMARD use.
Prescriber tendency and GC prescribing
In total 3270 GPs were assigned as primary prescribers.
The mean proportion of time their patients spent on GCs
ranged from 0 to 100 % (median 11.3 %, IQR 0.11–25.9 %).
GPs were thus categorised as ‘high’ prescribers if their pa-
tients spent a mean of ≥11.3 % of follow-up on GCs. A total
of 6427 (38.9 %) patients were assigned a ‘low’ GC pre-
scriber and 10,109 (61.1 %) were assigned a ‘high’ GC
prescriber.
By definition, the likelihood of a patient receiving a GC
prescription during follow-up was greater if they were
seen by a ‘high’ GC prescriber compared to a ‘low’ GC
prescriber (OR 3.10, 95 % CI 2.90–3.31). The probability
of receiving a GC prescription increased with each decade
of patient age for both ‘low’ (OR 1.15, 95 % CI 1.11–1.20)
and ‘high’ (OR 1.26, 95 % CI 1.23–1.29) prescriber groups
(Table 4). This effect differed significantly between the
two prescriber groups (p <0.001), suggesting that although
all older patients were more likely to receive GCs, the ef-
fect of age was greater in those seen by a ‘high’ prescriber.
In other words, high prescribers were even more likely to
prescribe GCs in elderly patients.
Table 2 Summary statistics of GC doses and duration of use per patient during follow-up and in the 12 months prior to study entry
for those patients ever prescribed GCs (n = 7777)
Follow-up period 12 months prior to study entry
Measure* Median IQR Median IQR
Duration of follow-up (years) 5.29 2.62–8.58 - -
Cumulative duration of GC use (years) 0.80 0.15–2.56 0.23 0.05–0.67
Proportion of follow-up time on GCs (%) 26.3 3.8–70.0 22.7 5.4–67.2
Average dose** (mg) 7.5 5–15.3 10 5–20
Lowest dose** (mg) 5 2.5–7.5 5 3–15
Highest dose** (mg) 15 7.5–30 15 6–30
GC glucocorticoid, IQR interquartile range
*Summary statistics were obtained by calculating the value for each patient and then determining median values across the whole population
**All doses are prednisolone-equivalent daily doses
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It was hypothesised that those with a greater ten-
dency to prescribe GCs may be prescribing inappro-
priately to those with baseline GC-associated
comorbidities. This was only seen for prescribers
whose patients had a baseline diagnosis of HTN, who
were more likely to receive a GC prescription in the
’high’ prescriber group (OR 1.29 95 % CI 1.17–1.42),
but not in the ‘low’ prescriber group (OR 1.08 95 %
CI 0.95–1.24), with the effect differing significantly
between groups (p = 0.039).
Discussion
This study set out to describe the utilisation of GC ther-
apy for RA in primary care, patterns of GC prescribing
and to examine the influence of patient factors and pre-
scriber tendency on GC prescribing amongst GPs for pa-
tients with RA. Nearly half the cohort received a GC
prescription in primary care during follow-up, consistent
with the findings of the QUEST-RA study [23]. The
population distribution of the mean prednisolone-
equivalent daily dose was 7.5 mg, taken for around 25 %
Table 3 Baseline patient characteristics associated with GC prescriptions





(odds ratio, 95 % CI)
Multivariate stepwise analysis
(odds ratio, 95 % CI)
Baseline demographics
Age (decades) 1.02, 1.02–1.02** 1.17, 1.14–1.20
Gender (female) 5313, 68.32 % 6153, 70.25 % 0.94, 0.88–1.00
Current smoking (versus never) 2147, 27.61 % 2385, 27.23 % 1.04, 1.00–1.08** 1.22, 1.13–1.32
Baseline GC-associated comorbidities
Osteoporosis 427, 5.49 % 279, 3.19 % 1.42, 1.21–1.66**
Avascular necrosis 7, 0.09 % 4, 0.05 % 1.68, 0.49–5.78
Myopathy 14, 0.18 % 10, 0.11 % 1.35, 0.60–3.08
Diabetes mellitus 603, 7.75 % 699, 7.98 % 0.85, 0.76–0.95** 0.71, 0.62–0.82
Cardiovascular disease 364, 4.68 % 264, 3.01 % 1.22, 1.04–1.44** 1.25, 1.03–1.51
Hypertension 1842, 23.69 % 1754, 20.03 % 0.98, 0.90–1.06
Hyperlipidaemia 798, 10.26 % 830, 9.48 % 0.93, 0.84–1.04 0.86, 0.76–0.97
Peptic ulcer disease 382, 4.91 % 334, 3.81 % 1.13, 0.97–1.32
Pancreatitis 46, 0.59 % 43, 0.49 % 1.11, 0.73–1.70
Depression 1684, 21.65 % 1847, 21.09 % 1.11, 1.03–1.19 **
Insomnia 985, 12.67 % 865, 9.88 % 1.21, 1.10–1.34**
Psychosis 56, 0.72 % 52, 0.59 % 1.24, 0.84–1.81
Baseline inflammatory comorbidities
Chronic obstructive pulmonary disease 540, 6.94 % 189, 2.16 % 2.74, 2.31–3.25** 1.63, 1.33–1.99
Asthma 1492, 19.18 % 925, 10.56 % 2.07, 1.89–2.27** 1.58, 1.42–1.76
Lower respiratory tract infection 1717, 22.08 % 1342, 15.44 % 1.47, 1.35–1.59** 1.22, 1.11–1.34
Inflammatory bowel disease 78, 1.11 % 63, 0.72 % 1.35, 0.96–1.89
Cutaneous lupus 13, 0.17 % 11, 0.13 % 1.30, 0.58–2.93
Cutaneous vasculitis 6, 0.08 % 0, 0.00 % 1
Atopic eczema 1084, 13.94 % 1127, 12.87 % 1.10, 1.00–1.20**
Baseline DMARD use
Methotrexate 465, 5.98 % 501, 5.72 % 1.07, 0.93–1.22 0.80, 0.66–0.97
Sulfasalazine 468, 6.02 % 581, 6.63 % 0.91, 0.80–1.03 0.69, 0.58–0.83
Hydroxychloroquine 259, 3.33 % 256, 2.92 % 1.20, 1.00–1.43**
Leflunomide 105, 1.35 % 71, 0.81 % 1.83, 1.35–2.49** 1.75, 1.18–2.59
Other DMARDs*** 277, 3.56 % 151, 1.72 % 2.06, 1.68–2.52** 1.68, 1.28–2.19
GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs, CI confidence interval
*Adjusted for age and gender
**Significant in univariate analysis
***Other DMARDs include gold, penicillamine, cyclosporine, chloroquine and azathioprine
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of follow-up time in GC users. This average dose of 7.5
mg is within the European League Against Rheumatism
(EULAR) definition of low-dose therapy of ≤7.5 mg per
day [24], and in keeping with studies reporting efficacy
[25–28] and reduced adverse effects with low-dose
therapy[4]. However, more than 50 % were prescribed
doses >10 mg per day at some point and nearly 20 %
were prescribed doses greater than 30 mg per day. The
indication for prescriptions is not available in CPRD,
therefore it is difficult to know whether high-dose ste-
roids were prescribed for the patient’s RA or for other
indications. The median cumulative duration of time
spent taking GCs was 0.8 years/10 months with the
interquartile range spanning from 0.15 years/2 months
to 2.56 years. This highlights that some patients are
taking GCs for longer than recommended [29], placing
them at increased risk of developing SEs [30, 31].
As expected, the presence of certain inflammatory co-
morbidities at diagnosis, in particular inflammatory lung
conditions, influenced GC prescribing. Of concern, GC
therapy was prescribed more commonly in certain
higher risk populations, including older patients and
those with CVD. These findings are in keeping with a
recent prospective RA study that found rheumatologists
were more likely to prescribe GCs and less likely to
commence DMARDs in patients who develop RA at an
older age, who were also more likely to have comorbidi-
ties including CVD, HTN and DM [32]. The authors
postulated that this might be due to clinician concerns
about the potential side effects of DMARDs in older pa-
tients, particularly those with more comorbidities. How-
ever, they also point out that DMARDs are well
tolerated in older patients [33] compared to the poten-
tial difficulties of GC SEs in older patients. It has been
shown that RA patients taking ≥7.5 mg prednisolone per
day are at increased risk of CVD [34, 35]. Pre-existing
CVD, HTN and smoking, an important risk factor for
CVD, may worsen cardiovascular outcomes further. Al-
though patients with baseline DM and hyperlipidaemia
received fewer GC prescriptions, it was also concerning
that other baseline conditions such as PUD had no influ-
ence on GC prescribing.
Baseline use of methotrexate and sulfasalazine was as-
sociated with less GC prescribing and is in keeping with
the knowledge that early treatment of RA within the
‘window of opportunity’ leads to lower disease activity
[36], and potentially reduced GC requirement. Several
studies have suggested that GC prescribing is also influ-
enced by biological DMARDs (bDMARDs), which have
been shown to have a GC-sparing effect [37–40]. In the
UK, bDMARDS can only be prescribed by rheumatolo-
gists and this data is therefore not captured by CPRD.
Table 4 Effect of baseline characteristics on GC prescriptions according to prescriber tendency
Variable Low prescriber group (OR, 95 % CI) High prescriber group (OR, 95 % CI) p value**
Demographics
Age (decades) 1.15, 1.11–1.20* 1.26, 1.23–1.29* <0.001
Gender (female) 0.98, 0.87–1.10 0.89, 0.82–0.97* 0.211
Current smoker (versus never) 1.09, 1.02–1.17* 1.07, 1.02–1.13* 0.744
GC-associated comorbidities
Osteoporosis 1.49, 1.14–1.95* 1.84, 1.50–2.25* 0.225
Avascular necrosis 2.28, 0.32–16.22 1.84, 0.36–9.51 0.870
Myopathy 2.29, 0.57–9.15 1.23, 0.45–3.38 0.479
Diabetes mellitus 0.88, 0.72–1.08 1.02, 0.88–1.18 0.257
Cardiovascular disease 1.38, 1.04–1.84* 1.62, 1.31–2.00* 0.373
Hypertension 1.08, 0.95–1.24 1.29, 1.17–1.41* 0.039
Hyperlipidaemia 1.10, 0.92–1.31 1.07, 0.94–1.22 0.829
Peptic ulcer disease 1.36, 1.06–1.74* 1.33, 1.09–1.63* 0.910
Pancreatitis 1.00, 0.49–2.05 1.44, 0.81–2.54 0.442
Depression 1.09, 0.96–1.23 1.09, 0.99–1.20 0.994
Insomnia 1.27, 1.08–1.50* 1.36, 1.20–1.54* 0.548
Psychosis 1.14, 0.60–2.17 1.29, 0.78–2.14 0.767
Prior use
GC prescription prior to follow up 6.52, 5.51–7.71* 11.76, 10.24–13.51* <0.001
GC glucocorticoid, OR odds ratio, CI confidence interval
*Significant predictors of GC prescriptions (unadjusted)
**p value indicates significance of any differing effect between high and low prescriber groups
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Therefore this study was unable to assess the influence
of these agents on GC prescribing.
The strengths of this study include the large cohort
size and the real-life setting in which CPRD data is cap-
tured. All oral GC prescriptions were recorded within
the database, meaning there was no missing prescription
data. The main limitation of this study design was the
lack of access to measures of disease activity, which
would be expected to be important in understanding
which patients receive GC prescriptions. The informa-
tion needed for standard measures of disease activity
such as EULAR response and disease activity score
(28-joint count) (DAS28) are not routinely collected
by GPs and were therefore not available on the CPRD
database. A second limitation of this study is that it
was unable to assess the influence of rheumatologist
prescribing practices or advice on GC prescribing in
primary care as rheumatologist prescribing data is not
captured in CPRD. However, it is likely that some GC
prescriptions will be initiated by a rheumatologist and
continued in primary care. On other occasions, GPs
may initiate GCs knowing that this is the practice/rec-
ommendation of the treating rheumatologist when
faced with active disease. This interaction between
prescribers is of interest and warrants further investi-
gation in the future.
Conclusions
In conclusion, this study has found that 50 % of patients
with incident RA were prescribed GCs in UK primary
care for 25 % of the time they were observed. Of those
who received GCs, more than 50 % were prescribed
doses >10 mg per day and nearly 20 % were prescribed
doses greater than 30 mg per day. Many GPs and rheu-
matologists may be surprised by the proportion of pa-
tients, the dosages prescribed and the duration of use of
GCs in primary care, highlighting the need to be aware
of GC use in this setting in order to avoid excess ex-
posure and associated side effects. Certain baseline co-
morbidities influenced GC prescribing, including some
high-risk patient groups that were more likely to re-
ceive GC prescriptions. This information is useful for
both rheumatologists and GPs involved in the care of
patients with RA because it highlights the extent of GC
prescribing in primary care and identifies at risk groups
more likely to receive GCs. Given the variety of treat-
ment options available for RA, it is important to con-
sider the individual patient’s specific comorbidities and
risk of developing GC SEs and introduce alternative
therapies where appropriate.
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